Laurus Labs reported a substantial improvement in profitability for the first quarter of FY27, with consolidated net profit after tax and share of profit from associates and joint ventures rising 124% year-on-year to ₹362.07 crore. The surge was underpinned by a 29.1% growth in revenue from operations, which reached ₹2,026.31 crore in the quarter ended June 30, 2026, compared to ₹1,569.57 crore in the corresponding period of FY26. Strong operational execution, particularly in the Contract Development and Manufacturing Organization (CDMO) segment, and favorable pricing dynamics contributed to expanded margins, positioning the pharmaceutical company for a robust start to the fiscal year.

The Board of Directors approved the unaudited standalone and consolidated financial results at a meeting held on July 24, 2026, in Hyderabad. The approval was made pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Deloitte Haskins & Sells LLP, the statutory auditors, conducted a limited review of the interim financial information in accordance with Standard on Review Engagements (SRE) 2410 issued by the Institute of Chartered Accountants of India. The auditors issued an unmodified conclusion, stating that nothing came to their attention to suggest the statements did not comply with Indian Accounting Standards (Ind AS) or contained material misstatements.

Financial Performance Overview

The company’s financial metrics reflect consistent growth across key parameters. Standalone net profit after tax stood at ₹289.96 crore, compared to ₹157.94 crore in Q1FY26. Revenue from operations on a standalone basis reached ₹1,757.16 crore, up from ₹1,432.75 crore in the previous year’s quarter. The following table details the consolidated financial highlights:

Total comprehensive income for the consolidated group amounted to ₹359.86 crore, compared to ₹160.97 crore in Q1FY26. The profit attributable to equity holders of the company was ₹367.60 crore. Earnings per share (basic) increased to ₹6.81 from ₹3.02 in the prior year quarter.

Segmental Growth and Strategic Updates

During the earnings call hosted on July 24, 2026, management highlighted significant acceleration in the CDMO business. Krishna Chaitanya Chava, Executive Director and Head CDMO, stated that the division reported a 69% growth with sales of ₹835 crore on the small molecule side. This growth was driven by acceleration in late-stage clinical and commercial deliveries for multiple global partners. Notably, 55% of small molecule CDMO revenue came from commercial supplies, up from 50% in the previous financial year.

The Affordable Medicines division also delivered strong performance, with revenue reaching ₹1,156 crore, a 10% year-on-year increase. Soumya Chava, Executive Director Generics and Commercial, noted that growth was driven by higher volumes across established portfolios, including Antiretrovirals (ARVs) and oncology products. Within ARV revenue, APIs contributed ₹415 crore and Finished Dosage Forms (FDF) contributed ₹254 crore, totaling ₹669 crore. The company maintains a mix where two-thirds of revenue is non-ARV and one-third is ARV.

Laurus Labs continues to advance its strategic restructuring initiatives. The Board had previously approved a Composite Scheme of Arrangement on August 21, 2025, involving the demerger of the identified business undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited. The scheme has been filed with the National Company Law Tribunal (NCLT), Amaravathi Bench, under Sections 230 and 232 of the Companies Act, 2013. Implementation remains subject to final approvals from the NCLT, with an appointed date proposed as April 01, 2026.

Capital Allocation and Forward Outlook

Management significantly revised its capital expenditure guidance for FY27. V. V. Ravi Kumar, Executive Director and CFO, disclosed that capex for the quarter stood at ₹394 crore. The full-year capex guidance has been raised from ₹1,000 crore to ₹1,500 crore, and subsequently to ₹2,000 crore during the Annual General Meeting. Satyanarayana Chava, Founder and CEO, explained that the increased investment is necessary to meet customer demands for capacity expansion in existing programs and new modalities such as peptides and Antibody-Drug Conjugates (ADCs).

The company’s net debt stood at ₹2,656 crore, resulting in a debt-to-EBITDA ratio of 1.28, slightly higher than 1.25 in the previous quarter due to capex plans. Return on Capital Employed (ROCE) improved to 19% from 17.7% in the previous year. Management reiterated its target to reach an asset turnover ratio of over 1.0 and a ROCE of 25% in the long term. Additionally, the company signed a development and commercial agreement with Aarvik Therapeutics for two ADC molecules for the India market and received final handover approval for a 500-plus acre land parcel from the Andhra Pradesh government.

Laurus Labs recorded a notable block trade on the National Stock Exchange (NSE), with approximately 95,224 shares changing hands at a price of ₹1780.10 per share. The total value of the transaction amounted to ₹16.95 crores, underscoring significant institutional or large investor activity in the stock.

Block Trade Details

The following table summarizes the key parameters of the Laurus Labs block trade executed on the NSE:

Significance of the Transaction

Block trades are large, privately negotiated securities transactions that are executed outside of the open market to minimize the impact on the stock's prevailing price. Such trades are typically carried out by institutional investors, mutual funds, or high-net-worth individuals. The execution of this block deal in Laurus Labs on the NSE reflects considerable interest from large market participants in the company's shares at the prevailing price level of ₹1780.10.